At a glance
- Originator Wakunaga Pharmaceutical
- Class Antibacterials; Quinolones
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 02 Jun 1998 Discontinued-Preclinical for Bacterial infections in Japan (Unknown route)
- 16 Feb 1995 No-Development-Reported for Bacterial infections in Japan (Unknown route)